Shire Plc (SHPG) announced that the FDA has approved its CUVITRU [Immune Globulin Subcutaneous (Human) 20% Solution] for the treatment of adult and pediatric patients at least two years old with primary immunodeficiency (PI), a group of over 300 genetic disorders in which the body's immune system fails to work properly. It affects ~6M people worldwide.